US President Donald Trump announced on Friday that his administration will impose a 100% tariff on branded and patented pharmaceuticals starting October 1, 2025, unless companies set up production in the US. The move directly impacts India’s pharmaceutical sector, particularly large drug makers increasingly focused on complex generics and biologics, which largely fall under the branded or patented category.

Indian pharmaceutical companies are increasingly focusing on complex generics, which are harder to replicate due to their sophisticated formulations or delivery mechanisms. This shift is aimed at accessing higher-value markets and reducing reliance on traditional generics. Firms such as Sun Pharmaceuticals, Dr. Reddy's Laboratories, Biocon, Aurobindo Pharma, Glenmark and Lupin have bee

See Full Page